Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2011. The report details a specific share repurchase transaction executed on July 26, 2011, authorized by shareholders at the Annual General Meeting held on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,692,532 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,375.0 pence per share; lowest price paid was 1,354.0 pence per share.
- Treasury Holdings (Settled): 490,504,284 shares (8.75% of total issued share capital).
- Treasury Holdings (Including Unsettled): 494,796,816 shares (9.68% of total voting rights).
- Shares in Issue: 5,113,325,888 shares (excluding treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,692,532 shares. Consequently, the Company's treasury holdings increased to represent 8.75% of total issued share capital, or 9.68% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The Company stated its intention to hold the purchased shares in Treasury.
Investor Verification Checklist
- Verify the total number of shares in issue (5,113,325,888) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current percentage of voting rights held in Treasury (9.68% including unsettled shares).
- Review the price range paid (1,354.0 to 1,375.0 pence) against market prices on July 26, 2011.
- Note that this filing does not contain financial performance metrics; refer to Form 20-F for comprehensive financial data.